Bronstein, Gewirtz & Grossman files class action lawsuit against Hims & Hers Health
News provided byHims & Hers Health, Inc · 1 min read
NEW YORK, Sept. 6, 2026 /CourierPR/ -- Bronstein, Gewirtz & Grossman, LLC, a leading investor-rights law firm, has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of its officers. The lawsuit seeks to recover damages from the defendants for alleged violations of federal securities laws on behalf of investors who purchased or otherwise acquired Hims securities between August 4, 2025, and July 29, 2026.
According to the Complaint, Hims & Hers Health, Inc. is accused of making materially false and misleading statements or failing to disclose critical information. Specifically, the lawsuit alleges that:
- Hims shared consumers' health information with third-party advertising platforms. - Hims charged consumers for prescriptions almost immediately after they submitted an intake form, despite claiming that consumers would be able to consult with a medical provider to find a treatment that is "right for them." - These actions subjected the company to regulatory scrutiny. - As a result, the company was reasonably likely to incur fees and penalties. - The company's positive statements about its business, operations, and prospects were materially misleading and lacked a reasonable basis.
Hims & Hers Health, Inc. investors who wish to participate in the lawsuit can review the Complaint by visiting the firm’s site or contacting Peretz Bronstein, Esq., or his Client Relations Manager, Nathan Miller, at 917-590-0911.
Bronstein, Gewirtz & Grossman, LLC represents investors in class actions on a contingency fee basis. This means that the firm will seek reimbursement for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if they are successful.
Peretz Bronstein, Founding Partner of the firm, stated, "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace."
For updates on the case, investors can follow the firm on LinkedIn, X, Facebook, or Instagram.